Novartis India Limited has officially communicated to BSE Limited regarding its upcoming Board of Directors meeting scheduled for January 28, 2026. The pharmaceutical company will consider and approve unaudited financial results for the quarter ended December 31, 2025, in compliance with regulatory requirements.

Board Meeting Schedule

The meeting has been scheduled pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The board will convene on Wednesday with the primary agenda being the consideration and approval of Q3FY26 unaudited financial results.

Trading Window Closure

In connection with the upcoming board meeting, Novartis India Limited has announced the closure of its trading window for designated persons. The trading window will be closed from Thursday, January 1, 2026, affecting designated persons, insiders, connected persons, and their immediate relatives.

Official Communication Details

The formal communication was addressed to BSE Limited at Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai. The announcement was digitally signed by Chandni Maru, Company Secretary and Compliance Officer (M No. A60291), on December 30, 2025.

The company operates from its registered office at Inspire-BKC in Mumbai's Bandra Kurla Complex and maintains transparency through regular compliance with stock exchange regulations and stakeholder communication requirements.

Novartis India Limited , a prominent player in the Indian pharmaceutical sector, has released its financial results for the second quarter, showcasing significant improvements across key metrics.

Financial Highlights

The company's performance for the quarter demonstrates strong growth and improved profitability:

Key Takeaways

1. Revenue Growth: Novartis India reported a 4.00% year-over-year increase in revenue, reaching ₹903.00 crore for the quarter.

2. EBITDA Performance: The company's EBITDA saw a substantial rise of 33.00%, climbing from ₹179.00 crore to ₹239.00 crore.

3. Margin Expansion: EBITDA margin expanded significantly, improving by 582 basis points to reach 26.44% compared to 20.62% in the same quarter last year.

4. Profit Increase: Net profit grew by 19.00%, rising from ₹204.00 crore to ₹242.00 crore year-over-year.

The robust financial performance indicates Novartis India's strong market position and operational efficiency. The significant improvement in EBITDA and EBITDA margin suggests effective cost management and potentially higher-value product sales.

Corporate Governance

As per the latest LODR (Listing Obligations and Disclosure Requirements) data, Novartis India's Board of Directors met on October 28, 2025, to approve the unaudited financial results for the quarter and half-year ended September 30, 2025. The meeting, which commenced at 11:35 AM (IST) and concluded at 2:45 PM (IST), also included a review of the Limited Review Report issued by the company's Statutory Auditors.

This timely disclosure aligns with regulatory requirements and demonstrates Novartis India's commitment to transparency and corporate governance standards.

Investors and stakeholders can access the detailed financial results and the Limited Review Report on the company's official website at www.novartis.com/in-en/ .

As Novartis India continues to navigate the dynamic pharmaceutical landscape, these results reflect its resilience and ability to drive growth in a competitive market. Stakeholders will likely keep a close eye on how the company maintains this momentum in the coming quarters.